Key Takeaways:
Bleichmar Fonti & Auld LLP opened a securities fraud probe into IBM after the stock plunged 25 percent on July 14, erasing $68 billion in market value.
The investigation targets whether IBM misled investors about the pace of securing new business deals and the strength of its IBM Z mainframe outlook, the firm said.
IBM reported on July 14 that a shortfall in its Z performance and associated software stack, primarily in Transaction Processing, drove the miss. The company said numerous large deals failed to close on expected timelines because it did not "adapt and move quickly enough." The stock fell $73.16 to close at $217.07.
The probe adds legal risk to a stock already down sharply. Pomerantz LLP, Glancy Prongay Wolke & Rotter LLP, and Levi & Korsinsky LLP have also opened investigations into IBM's disclosures.
The scrutiny follows a sharp reversal from IBM's April guidance, when executives described a "record start" for the z17 product with IBM Z revenue rising 51 percent in Q1. Total revenue growth came in at 1 percent in Q2, versus the 5 percent-plus projected in April, while infrastructure revenue swung from plus 15 percent in Q1 to minus 7 percent.
IBM posted Q2 revenue of $17.16 billion, beating the consensus estimate of $16.86 billion, with adjusted earnings of $2.93 per share ahead of the $2.86 expected. CEO Arvind Krishna attributed the miss to customers reprioritizing capital expenditure and said about 40 percent of the deferred deals had already closed within three to four weeks, framing the shortfall as a deferral rather than lost business.
Management expects two-thirds to three-quarters of the slipped deals to close within six months. Generative AI accounted for roughly 50 percent of signings in Q2 but failed to offset the decline in traditional transaction processing revenue.
BFA, which recovered more than $900 million from Tesla's board and $420 million from Teva Pharmaceutical, is representing investors on a contingency basis. The firm said shareholders are not responsible for court costs or litigation expenses.
The probe leaves IBM exposed to potential class-action claims on top of a 25 percent valuation reset, testing investor confidence in management's forward guidance. Investors will watch whether the deferred mainframe deals close by year-end, with management's six-month window ending in January.
This article is for informational purposes only and does not constitute investment advice.
